Compare VTRS & CSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTRS | CSL |
|---|---|---|
| Founded | 1961 | 1917 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Specialty Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 13.4B |
| IPO Year | N/A | N/A |
| Metric | VTRS | CSL |
|---|---|---|
| Price | $10.96 | $325.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $11.17 | ★ $386.67 |
| AVG Volume (30 Days) | ★ 7.8M | 447.5K |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | ★ 4.39% | 1.36% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 17.56 |
| Revenue | ★ $14,124,400,000.00 | $5,015,100,000.00 |
| Revenue This Year | N/A | $1.17 |
| Revenue Next Year | $1.16 | $2.98 |
| P/E Ratio | ★ N/A | $18.43 |
| Revenue Growth | N/A | ★ 0.14 |
| 52 Week Low | $6.85 | $293.43 |
| 52 Week High | $13.13 | $440.73 |
| Indicator | VTRS | CSL |
|---|---|---|
| Relative Strength Index (RSI) | 60.39 | 54.88 |
| Support Level | $10.67 | $313.97 |
| Resistance Level | $10.93 | $324.30 |
| Average True Range (ATR) | 0.24 | 8.93 |
| MACD | 0.01 | 2.60 |
| Stochastic Oscillator | 90.23 | 87.75 |
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Carlisle Companies Inc is a holding company. The company manufactures and sells single-ply roofing products and warranted systems and accessories for the commercial building industry. The company is organized into two segments including Carlisle Construction Materials and Carlisle Weatherproofing Technologies. The company's product portfolio includes moisture protection products, protective roofing underlayments, integrated air and vapor barriers, spray polyurethane foam and coating systems, and others. The majority of the company's revenue comes from the Carlisle Construction Materials segment, and more than half of the total revenue is earned in the United States.